South Korean fabless producer Dongwoon Anatech is looking for the approval of each the US and Korean Food and Drug Administration for the industrial rollout of its saliva-based glucose monitoring machine after finishing its first scientific trial in December.
WHAT IT DOES
The sugar monitoring machine known as D-SaLife, a product of six years of analysis and improvement, makes use of microcurrent management expertise in figuring out the glucose degree current in an individual’s saliva pattern. The meter color codes the results of the studying which can also be recorded by way of a cellular app.
WHY IT MATTERS
Dongwoon carried out its first exploratory scientific trial in Nowon Eulji Medical Center – a college hospital in Seoul – involving 114 diabetic outpatients. The KOSDAQ-listed chipmaker can also be planning to conduct D-SaLife’s scientific trials within the US, although it has not disclosed a date for it.
The firm already secured patent recognition for the expertise behind D-SaLife in South Korea, Japan and China with extra patent purposes pending in Europe, India and the US.
D-SaLife is just not the one saliva-based glucose check mechanism current as we speak. In 2019, Australian biotech firm iQ Global Group launched its Saliva Glucose Biosensor, a small disposable strip that when uncovered to saliva will transmit a sugar degree measurement to a close-by smartphone.
Non-prick, wearable steady glucose displays are additionally being marketed around the globe, like Abbott’s FreeStyle Libre 2 and Symphony by Echo Therapeutics, an early participant on this house. Health tech startup Movano can also be developing with a radio frequency-powered CGM. Moreover, there are additionally minimally invasive ones such because the Dexcom G6 and Biolinq’s upcoming CGM that makes use of a biosensor.
By 2025, the global digital diabetes management market is estimated to achieve $17.09 billion at a CAGR of 23%. In 2019, about one in 11 adults suffered from diabetes or about 463 million folks worldwide, information from the International Diabetes Federation has proven.
ON THE RECORD
“Dongwoon Anatech challenges the healthcare market with semiconductor innovation technology and know-how that [we have] accumulated for more than 20 years as a key player of the semiconductor industry,” Dongwoon CEO Kim Dongcheol instructed Mobihealth News.
“We will become a leader [in diagnostics], focusing on improving the lives of patients and their families through D-SaLife,” he added.